Literature DB >> 27355872

TCGA: Increased oncoprotein coding region mutations correlate with a greater expression of apoptosis-effector genes and a positive outcome for stomach adenocarcinoma.

John M Yavorski1, George Blanck1,2.   

Abstract

Oncogene mutations are primarily thought to facilitate uncontrolled cell growth. However, overexpression of oncoproteins likely leads to apoptosis in a feed forward mechanism, whereby a certain level of oncoprotein leads to the activation of pro-proliferation effector genes and higher levels lead to activation of pro-apoptotic effector genes. TCGA STAD barcodes having no oncoprotein coding region mutations represented reduced expression of the apoptosis-effector genes compared with barcodes with multiple oncoprotein coding region mutations. Furthermore, STAD barcodes in a "no-subsequent tumor" group, representing 224 samples, and in a "positive outcome" group, had more oncoprotein coding regions mutated, on average, than barcodes of the new tumor and negative outcome groups, respectively. BRAF, CTNNB1, KRAS and MTOR coding region mutations (as a group) had the strongest association with the no-subsequent tumor group. Tumor suppressor coding region mutations were also correlated with no-subsequent tumor. These results are consistent with an oncoprotein-mediated, feed-forward mechanism of apoptosis in patients. Importantly, the no-subsequent tumor group also had more overall mutations. This result leads to considerations of unhealthy cells or cells with more neo-antigens for immune rejection. However, a probabilistic aspect of mutagenesis is also consistent with more oncoprotein and tumor suppressor protein mutations, in cases of more overall mutations, and thus a higher likelihood of activation of feed forward apoptosis pathways.

Entities:  

Keywords:  apoptosis-effector genes; feed-forward apoptosis; oncoprotein mediated apoptosis; stomach adenocarcinoma; tumor suppressor proteins

Mesh:

Substances:

Year:  2016        PMID: 27355872      PMCID: PMC4993568          DOI: 10.1080/15384101.2016.1195532

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  36 in total

1.  E2F-1 functions in mice to promote apoptosis and suppress proliferation.

Authors:  S J Field; F Y Tsai; F Kuo; A M Zubiaga; W G Kaelin; D M Livingston; S H Orkin; M E Greenberg
Journal:  Cell       Date:  1996-05-17       Impact factor: 41.582

2.  Tumor induction and tissue atrophy in mice lacking E2F-1.

Authors:  L Yamasaki; T Jacks; R Bronson; E Goillot; E Harlow; N J Dyson
Journal:  Cell       Date:  1996-05-17       Impact factor: 41.582

3.  The E2F transcription factor activates a replication-dependent human H2A gene in early S phase of the cell cycle.

Authors:  F Oswald; T Dobner; M Lipp
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

4.  Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN.

Authors:  T Teitz; T Wei; M B Valentine; E F Vanin; J Grenet; V A Valentine; F G Behm; A T Look; J M Lahti; V J Kidd
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

5.  The nuclear protein UHRF2 is a direct target of the transcription factor E2F1 in the induction of apoptosis.

Authors:  Huarui Lu; Timothy C Hallstrom
Journal:  J Biol Chem       Date:  2013-07-05       Impact factor: 5.157

6.  Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN.

Authors:  Tal Teitz; Tie Wei; Dong Liu; Virginia Valentine; Marcus Valentine; Jose Grenet; Jill M Lahti; Vincent J Kidd
Journal:  Oncogene       Date:  2002-03-14       Impact factor: 9.867

7.  Stimulation of CD30 in anaplastic large cell lymphoma leads to production of nuclear factor-kappaB p52, which is associated with hyperphosphorylated Bcl-3.

Authors:  Momoko Nishikori; Hitoshi Ohno; Hironori Haga; Takashi Uchiyama
Journal:  Cancer Sci       Date:  2005-08       Impact factor: 6.716

8.  Hypothesis: breast cancer regression under oestrogen therapy.

Authors:  B A Stoll
Journal:  Br Med J       Date:  1973-08-25

9.  Enhanced T cell apoptosis within Drak2-deficient mice promotes resistance to autoimmunity.

Authors:  Stephanie J Ramos; Jeniffer B Hernandez; Martina Gatzka; Craig M Walsh
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

10.  Regulation of adenovirus 12 E1A transcription: E2F and ATF motifs in the E1A promoter bind nuclear protein complexes including E2F1, DP-1, cyclin A and/or RB and mediate transcriptional (auto)activation.

Authors:  H C Kirch; B Pützer; G Schwabe; H K Gnauck; H Schulte Holthausen
Journal:  Cell Mol Biol Res       Date:  1993
View more
  5 in total

1.  Identification of specific feed-forward apoptosis mechanisms and associated higher survival rates for low grade glioma and lung squamous cell carcinoma.

Authors:  Dhiraj Sikaria; Yaping N Tu; Diana A Fisler; James A Mauro; George Blanck
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-05       Impact factor: 4.553

2.  Elucidating feed-forward apoptosis signatures in breast cancer datasets: Higher FOS expression associated with a better outcome.

Authors:  Diana A Fisler; Dhiraj Sikaria; John M Yavorski; Yaping N Tu; George Blanck
Journal:  Oncol Lett       Date:  2018-06-12       Impact factor: 2.967

3.  Retinoblastoma tumor cell proliferation is negatively associated with an immune gene expression signature and increased immune cells.

Authors:  Aaron L Sarver; Chencheng Xie; Megan J Riddle; Colleen L Forster; Xiaohong Wang; Huarui Lu; Wyatt Wagner; Jakub Tolar; Timothy C Hallstrom
Journal:  Lab Invest       Date:  2021-03-03       Impact factor: 5.662

4.  Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235.

Authors:  Chencheng Xie; Matthew J Freeman; Huarui Lu; Xiaohong Wang; Colleen L Forster; Aaron L Sarver; Timothy C Hallstrom
Journal:  Oncotarget       Date:  2017-06-13

5.  An age-based, RNA expression paradigm for survival biomarker identification for pediatric neuroblastoma and acute lymphoblastic leukemia.

Authors:  Andrea Diviney; Boris I Chobrutskiy; Saif Zaman; George Blanck
Journal:  Cancer Cell Int       Date:  2019-03-27       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.